| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0026 | 1 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.00096 | 1 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.00059 | 1 |